{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:53:22Z","timestamp":1761947602820},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.ejso.2009.12.003","type":"journal-article","created":{"date-parts":[[2010,1,15]],"date-time":"2010-01-15T06:06:11Z","timestamp":1263535571000},"page":"541-545","source":"Crossref","is-referenced-by-count":7,"title":["Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: A word of caution for oral surgeons and oncologists"],"prefix":"10.1016","volume":"36","author":[{"given":"P.","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.S.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Chaukar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"D'cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2009.12.003_bib1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates; a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ejso.2009.12.003_bib2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaw","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Int Med"},{"key":"10.1016\/j.ejso.2009.12.003_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2009.12.003_bib4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2009.12.003_bib5","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMp038176","article-title":"A new insight into the formation of osteolytic lesions in multiple myeloma","volume":"349","author":"Glass","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2009.12.003_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JOP.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ejso.2009.12.003_bib7","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bannias","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2009.12.003_bib8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2009.12.003_bib9","doi-asserted-by":"crossref","first-page":"5057a","DOI":"10.1182\/blood.V106.11.5057.5057","article-title":"Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw","volume":"106","author":"Pozzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejso.2009.12.003_bib10","first-page":"99","article-title":"Osteonecrosis of the jaw and bisphosphonates (correspondence)","volume":"3531","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2009.12.003_bib11","doi-asserted-by":"crossref","first-page":"3461a","DOI":"10.1182\/blood.V106.11.3461.3461","article-title":"Bisphosphonates and osteonecrosis of the jaws: incidence in a homogenous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid","volume":"106","author":"Tosi","year":"2005","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1016\/j.ejso.2009.12.003_bib12","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/j.seminoncol.2007.10.007","article-title":"Safety profile of intravenous bisphosphonates","volume":"34","author":"Mehrotra","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejso.2009.12.003_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.ejso.2009.12.003_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1385\/MO:23:1:51","article-title":"Jaw complications associated with bisphosphonates use in patients with plasma cell dyscrasias","volume":"23","author":"Thakkar","year":"2006","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejso.2009.12.003_bib15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798309005447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798309005447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T20:10:24Z","timestamp":1590523824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798309005447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0748798309005447"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2009.12.003","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}